SPO Global Inc - SPOM stock
OTC Symbol: SPOM | OTC Tier: Pink Current
About SPOM[edit]
SPO Global (OTC: SPOM) owns Gerpang Healthcare Group which is a bio-pharmaceutical company, located in Yaogu Industrial Park, that manufactures stents, vaccines, monoclonal antibodies for male infertility detection, cognitive disorder functional food, and polypeptide probiotics.[1] SPO Global is based in Jinan, China, was founded in 2006, and completed a merger with Gerpang Healthcare Group in early 2020.[2]
[edit]
In a letter to shareholders dated 5/10/2022, SPO provided an update on the company's progress over the past year, including the acquisition of Gerpang Healthcare. The acquisition has allowed SPO Global to expand its offerings and diversify its revenue streams. The letter also discusses the impact of the COVID-19 pandemic on the healthcare industry and how SPO Global has responded by providing various products and services related to COVID-19 testing and treatment. Additionally, the letter outlines the company's plans for the future, which includes expanding its global reach and developing new technologies and products.[3]
Partnerships[edit]
Cinuo Traditional Chinese Medicine Science and Technology Group[edit]
SPO Global has a partnership between Cinuo Traditional Chinese Medicine Science and Technology Group Co., Ltd. and Spun SPO Medical Group, a subsidiary of Gerbang Medical, which was acquired by SPO Global in 2021. The partnership aims to develop and distribute traditional Chinese medicine (TCM) products and services globally. Specifically, the partnership will focus on developing TCM treatments for respiratory diseases, including COVID-19. TCM has been used in China for thousands of years and has been shown to have potential in treating various diseases. The partnership between Cinuo and Spun SPO Medical Group aims to bring TCM treatments to a wider audience and to combine TCM with Western medicine to provide more comprehensive healthcare solutions.[4]
Qingdao Fuyutang Health Development Ltd.[edit]
SPO Global Inc.'s subsidiary, Gerpang Healthcare Group, has a partnership with Qingdao Fuyutang Health Development Ltd. The partnership aims to provide medical products and services to the Chinese market, including but not limited to personal protective equipment (PPE), medical equipment, and healthcare management services. The partnership is based on mutual trust and understanding, and both companies are committed to providing high-quality products and services to customers in China. The partnership is expected to leverage the strengths of both companies and to create new business opportunities in the healthcare industry in China.[5]
Financial Performance[edit]
Total revenue for the year ending 12/31/2021 was $31,766,000 with net income of $2,377,000. Q1 2022 showed a decline in revenue of 37% from $4,926,000 to $3,119,000 compared to the quarter ending 3/31/2021. Cash on hand at 12/31/2021 was $1,023,000 with $0 long term debt.[6]
Total revenue for the year ending 12/31/2022 was $3,119,000 with net income of $54,000. Cash on hand at 12/31/2021 was $1,095,000 with $0 long term debt.[6]
- ↑ Yahoo Finance. SPOM Stock Profile. Retrieved on 8/28/2022
- ↑ Globe Newswire. SPO Global and Gerpang Healthcare Group Complete Merger Agreement. February 19, 2020
- ↑ Globe Newswire. SPO Global Inc. Issues Letter to Shareholders. May 10, 2022.
- ↑ Globe Newswire. SPO Global Inc. Announces Partnership Between Cinuo Traditional Chinese Medicine, Science and Technology Group Co., Ltd and Spun SPO Medical (Group), a subsidiary of Gerbang Medical. March 29, 2022.
- ↑ Globe Newswire. SPO Global’s subsidiary Gerpang Healthcare Group and Qingdao Fuyutang Health Development Ltd. Announce Partnership. March 10, 2020.
- ↑ 6.0 6.1 OTC Markets. SPOM Stock Financials. Retrieved on 8/28/2022
